HALO
NASDAQ · Biotechnology
Halozyme Therapeutics Inc
$64.12
-1.07 (-1.64%)
Performance
1D
—
1W
—
1M
—
3M
-20.33%
6M
-5.72%
1Y
-2.66%
YTD
-8.80%
Open$65.44
Previous Close$65.19
Day High$65.78
Day Low$64.00
52W High$82.22
52W Low$47.50
Volume—
Avg Volume1.23M
Market Cap7.70B
P/E Ratio24.29
EPS$2.49
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$71.23
Below
SMA 200
$65.75
Below
RSI (14)
47.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Buy
15 analysts
Price Target
-67.2% upside
Current
$64.12
$64.12
Target
$21.02
$21.02
$15.29
$21.02 avg
$24.22
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.35B | 1.05B | 1.30B |
| Net Income | 307.01M | 215.23M | -74,995,325 |
| Profit Margin | 22.7% | 21.6% | -5.8% |
| EBITDA | 523.37M | 387.29M | -91,476,031 |
| Free Cash Flow | — | — | -86,399,966 |
| Rev Growth | +28.4% | +28.4% | +13.4% |
| Debt/Equity | 43.89 | 43.89 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |